Earnings Summary

Ultragenyx Pharmaceutical Inc.’s revenue jumped 8.3% since last year same period to $108.83Mn in the Q1 2024. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated -14.57% fall in its revenue since last 3-months.

Ultragenyx Pharmaceutical Inc.’s net profit fell -4.09% since last year same period to $-170.68Mn in the Q1 2024. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated -38.55% fall in its net profits since last 3-months.

Ultragenyx Pharmaceutical Inc.’s net profit margin jumped 3.88% since last year same period to -156.83% in the Q1 2024. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated -62.18% fall in its net profit margins since last 3-months.

Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) estimates for the current year stand at -1.75.

Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) jumped 12.88% since last year same period to -2.03 in the Q1 2024. This indicates that the Ultragenyx Pharmaceutical Inc. has generated 12.88% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ultragenyx Pharmaceutical Inc.’s return on assets (ROA) stands at -0.27.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ultragenyx Pharmaceutical Inc.’s return on equity (ROE) stands at -3.4.